| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Laura Brandt, Jermaine D Jones, Suky Martinez, Jeanne M Manubay, Shanthi Mogali, Tatiana Ramey, Frances R Levin, Sandra D Come. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug and alcohol dependence. vol 208. 2021-01-18. PMID:31980285. |
lorcaserin, a high-affinity 5-ht |
2021-01-18 |
2023-08-13 |
human |
| Sanjay Sharma, Komal S Aware, Ketan Hatware, Kiran Pati. Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update. Mini reviews in medicinal chemistry. vol 20. issue 9. 2021-01-15. PMID:30961494. |
chemistry, analysis, pharmacokinetics and pharmacodynamics aspects of lorcaserin, a selective serotonin 5-ht2c receptor agonist: an update. |
2021-01-15 |
2023-08-13 |
rat |
| Sanjay Sharma, Komal S Aware, Ketan Hatware, Kiran Pati. Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update. Mini reviews in medicinal chemistry. vol 20. issue 9. 2021-01-15. PMID:30961494. |
lorcaserin hcl is a novel, synthetic, centrally-acting selective serotonin c (5-ht2c) receptor, l agonist, which results in increased satiety and decreased food consumption in patients. |
2021-01-15 |
2023-08-13 |
rat |
| Mauro Cataldi, Angelo Cignarelli, Francesco Giallauria, Giovanna Muscogiuri, Luigi Barrea, Silvia Savastano, Annamaria Cola. Cardiovascular effects of antiobesity drugs: are the new medicines all the same? International journal of obesity supplements. vol 10. issue 1. 2021-01-01. PMID:32714509. |
finally, lorcaserin, a selective 5ht |
2021-01-01 |
2023-08-13 |
Not clear |
| Luiz Ricardo de Almeida Kiguti, Tainá Louise Pacheco, Edson Antunes, Wilma de Grava Kempina. Lorcaserin Administration has Pro-Ejaculatory Effects in Rats via 5-HT The journal of sexual medicine. vol 17. issue 6. 2020-12-21. PMID:32234370. |
lorcaserin administration has pro-ejaculatory effects in rats via 5-ht lorcaserin is an anti-obesity drug whose weight loss effect results from 5-hydroxytryptamin (5-ht) |
2020-12-21 |
2023-08-13 |
rat |
| Hsiao-Huai Kuo, Kuang-Te Wang, Ying-Hsiang Lee, Po-Lin Lin, Ming-En Liu, Chien-Yu Lin, Lawrence Yu-Min Li. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. Journal of clinical pharmacy and therapeutics. vol 45. issue 1. 2020-10-07. PMID:31544267. |
lorcaserin is a selective serotonin 2c receptor agonist approved as an anti-obesity agent. |
2020-10-07 |
2023-08-13 |
Not clear |
| Ryan T Hurt, Manpreet S Mundi, Jon O Ebber. Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 11. 2020-10-01. PMID:30233224. |
lorcaserin is thought to reduce weight by targeting the serotonin (5ht |
2020-10-01 |
2023-08-13 |
Not clear |
| H Bays, C Perdomo, E Nikonova, R Knoth, M Malhotr. Lorcaserin and metabolic disease: weight-loss dependent and independent effects. Obesity science & practice. vol 4. issue 6. 2020-10-01. PMID:30574343. |
lorcaserin is a selective 5-hydroxytryptamine 2c receptor agonist. |
2020-10-01 |
2023-08-13 |
Not clear |
| Giuseppe Di Giovanni, Rahul Bharatiya, Emilie Puginier, Marta Ramos, Salomé De Deurwaerdère, Abdeslam Chagraoui, Philippe De Deurwaerdèr. Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain. Frontiers in pharmacology. vol 11. 2020-09-28. PMID:32714188. |
lorcaserin alters serotonin and noradrenaline tissue content and their interaction with dopamine in the rat brain. |
2020-09-28 |
2023-08-13 |
rat |
| Giuseppe Di Giovanni, Rahul Bharatiya, Emilie Puginier, Marta Ramos, Salomé De Deurwaerdère, Abdeslam Chagraoui, Philippe De Deurwaerdèr. Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain. Frontiers in pharmacology. vol 11. 2020-09-28. PMID:32714188. |
lorcaserin is a preferential serotonin2c receptor (5-ht |
2020-09-28 |
2023-08-13 |
rat |
| Hai Zeng, Meng Luo, Zunjiang Li, Junru Wen, Guoxin He, Yuelin Jin, Wenbin Fu, Peng Zho. Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis. BMJ open. vol 9. issue 7. 2020-07-23. PMID:31352420. |
lorcaserin is a selective 5-hydroxytryptamine 2c agonist which exerts robust benefits on long-term weight loss by suppressing appetite among adults with overweight or obesity. |
2020-07-23 |
2023-08-13 |
Not clear |
| Dario Tuccinardi, Olivia M Farr, Jagriti Upadhyay, Sabrina M Oussaada, Hannah Mathew, Stavroula A Paschou, Nikolaos Perakakis, Anastasia Koniaris, Theodoros Kelesidis, Christos S Mantzoro. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial. Diabetes, obesity & metabolism. vol 21. issue 6. 2020-05-29. PMID:30724455. |
lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. |
2020-05-29 |
2023-08-13 |
human |
| Paul J Fletcher, Zhaoxia Li, Leo B Silenieks, Cam MacMillan, Ines DeLannoy, Guy A Higgin. Preclinical evidence for combining the 5-HT Addiction biology. vol 24. issue 3. 2020-05-18. PMID:29498158. |
lorcaserin, a 5-ht |
2020-05-18 |
2023-08-13 |
Not clear |
| Susan L McElroy, Anna I Guerdjikova, Nicole Mori, Francisco Romo-Nav. Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa. CNS drugs. vol 33. issue 1. 2020-03-10. PMID:30523523. |
preclinical models suggest that nociceptin receptor antagonists, the selective serotonin 5-ht2c receptor agonist lorcaserin, monoamine stabilizers, and selective orexin-1 receptor antagonists might be helpful. |
2020-03-10 |
2023-08-13 |
Not clear |
| Jimmie L Pirtle, Melissa D Hickman, Varun C Boinpelly, Kamalakar Surineni, Hemant K Thakur, Kenneth W Grasin. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacology, biochemistry, and behavior. vol 180. 2020-03-10. PMID:30811963. |
lorcaserin is a modestly selective agonist for 2c serotonin receptors (5-ht |
2020-03-10 |
2023-08-13 |
human |
| Benjamin M Scirica, Erin A Bohula, Jamie P Dwyer, Arman Qamar, Silvio E Inzucchi, Darren K McGuire, Anthony C Keech, Steven R Smith, Sabina A Murphy, Kyungah Im, Lawrence A Leiter, Milan Gupta, Tushar Patel, Wenfeng Miao, Carlos Perdomo, Marc P Bonaca, Christian T Ruff, Marc S Sabatine, Stephen D Wiviot. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. vol 139. issue 3. 2019-10-28. PMID:30586726. |
lorcaserin, a selective serotonin 2c receptor agonist that promotes appetite suppression, led to sustained weight loss without any increased risk for major adverse cardiovascular (cv) events in the camellia-timi 61 trial (cardiovascular and metabolic effects of lorcaserin in overweight and obese patients-thrombolysis in myocardial infarction 61). |
2019-10-28 |
2023-08-13 |
Not clear |
| Brenda M Gannon, Agnieszka Sulima, Kenner C Rice, Gregory T Collin. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats. The Journal of pharmacology and experimental therapeutics. vol 364. issue 2. 2019-05-17. PMID:29217539. |
lorcaserin is a serotonin (5-ht) |
2019-05-17 |
2023-08-13 |
rat |
| Erin A Bohula, Benjamin M Scirica, Christina Fanola, Silvio E Inzucchi, Anthony Keech, Darren K McGuire, Steven R Smith, Tim Abrahamsen, Bruce H Francis, Wenfeng Miao, Carlos A Perdomo, Andrew Satlin, Stephen D Wiviott, Marc S Sabatin. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American heart journal. vol 202. 2019-05-03. PMID:29803985. |
lorcaserin, a selective serotonin 2c receptor agonist, is an effective pharmacologic weight-loss therapy that improves several cardiovascular risk factors. |
2019-05-03 |
2023-08-13 |
Not clear |
| Lisa R Gerak, Gregory T Collins, David R Maguire, Charles P Franc. Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys. Experimental and clinical psychopharmacology. vol 27. issue 1. 2019-03-15. PMID:30382731. |
agonists at serotonin (5-ht)2c receptors, particularly lorcaserin, are being considered as pharmacotherapies for abuse of a variety of drugs, including cocaine and opioids. |
2019-03-15 |
2023-08-13 |
monkey |
| Sarah A Blumenthal, Wayne E Prat. d-Fenfluramine and lorcaserin inhibit the binge-like feeding induced by μ-opioid receptor stimulation of the nucleus accumbens in the rat. Neuroscience letters. vol 687. 2019-03-11. PMID:30227154. |
these experiments assessed the effects of systemic treatments with the serotonin agonists d-fenfluramine and lorcaserin on the binge-like feeding induced by μ-opioid receptor stimulation of the nacc in sprague-dawley rats. |
2019-03-11 |
2023-08-13 |
rat |